

7. Literatur

1. Egan KM, Seddon JM, Glynn RJ, Gragoudas ES, Albert DM. Epidemiologic aspects of uveal melanoma. *Surv Ophthalmol* 1988, 32:239-251.
2. Robertson DM. Changing concepts in the management of choroidal melanoma. *Am J Ophthalmol* 2003, 136:161-170.
3. Shields JA, Shields CL, Donoso LA. Management of posterior uveal melanoma. *Surv Ophthalmol* 1991, 36:161-195.
4. Assessment of metastatic disease status at death in 435 patients with large choroidal melanoma in the Collaborative Ocular Melanoma Study (COMS). *Arch Ophthalmol* 2001, 119:670-676.
5. Bedikian AY, Legha SS, Mavligit G, et al. Treatment of uveal melanoma metastatic to the liver: a review of the M. D. Anderson Cancer Center experience and prognostic factors. *Cancer* 1995, 76:1665-1670.
6. Gragoudas ES, Egan KM, Seddon JM, et al. Survival of patients with metastases from uveal melanoma. *Ophthalmology* 1991, 98:383-389.
7. Kath R, Hayungs J, Bornfeld N, Sauerwein W, Hoffken K, Seeber S. Prognosis and treatment of disseminated uveal melanoma. *Cancer* 1993, 72:2219-2223.
8. Singh AD, Shields CL, Shields JA. Prognostic factors in uveal melanoma. *Melanoma Res* 2001, 11:255-263.
9. Diener-West M, Hawkins BS, Markowitz JA, Schachat AP. A review of mortality from choroidal melanoma. II. A meta-analysis of 5-year mortality rates following enucleation, 1966 through 1988. *Arch Ophthalmol* 1992, 110:245-250.
10. Renkvist N, Castelli C, Robbins PF, Parmiani G. A listing of human tumor antigens recognized by T cells. *Cancer Immunol Immunother* 2001, 50:3-15.
11. Nasi ML, Lieberman P, Busam KJ, Prieto V, Panageas KS, Lewis JJ, Houghton AN, Chapman PB. Intradermal injection of granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with metastatic melanoma recruits dendritic cells. *Cytokines Cell Mol Ther* 1999, 5:139-44.
12. Scheibenbogen C, Nagorsen D, Seliger B, Schmittel A, Letsch A, Bauer S, Max N, Bock M, Atkins D, Thiel E, Keilholz U. Long-term freedom from recurrence in 2 stage IV melanoma patients following vaccination with tyrosinase peptides. *Int J Cancer*, 2002, 99:403-408.
13. Scheibenbogen C, Romero P, Rivoltini L, Herr W, Schmittel A, Cerottini JC, Woelfel T, Eggermont AMM, Keilholz U. Quantitation of antigen-reactive T cells in peripheral blood by IFN-gamma ELISPOT assay and chromium release assay: A four-centre comparative trial. *J. Immunol Methods*, 2000, 244:81-89.
14. Scheibenbogen C, Schadendorf D, Bechrakis NE, Nagorsen D, Hofmann U, Servetopoulou F, Letsch A, Philipp A, Foerster MH, Schmittel A, Thiel E, Keilholz U. Effects of granulocyte-macrophage colony-stimulating factor and foreign protein as immunologic adjuvants on T-cell response to vaccination with tyrosinase peptides. *Int J Cancer*, 2003, 104:188-194.
15. Myatt N, Cree IA, Kurbacher CM, Foss AJE, Hungerford JL, Plowman PN. The ex vivo chemosensitivity profile of choroidal melanoma. *Anticancer drugs* 1997, 8:756-762.
16. Neale MH, Myatt N, Cree IA, et al. Combination chemotherapy for choroidal melanoma: ex vivo sensitivity to treosulfan with gemcitabine or cytosine arabinoside. *Br J Cancer*, 1999, 79:1487-1493.

17. Peters GJ, Ruiz van Haperen VW, Bergman AM, Verman G, Smitskamp-Wilms E, van Moorsel CJ, Kuiper CM, Braakhuis BJ. Preclinical combination therapy with gemcitabine and mechanisms of resistance. *Semin Oncol* 1996, 25:16-24.
18. Iwasaki H, Huang P, Keating MJ, Plunkett W. Differential incorporation of ara-C, gemcitabine, and fludarabine into replicating and repairing DNA in proliferating human leukemia cells. *Blood* 1997, 90:270-278.
19. Keilholz U, Schuster R, Schmittel A, Bechrakis N, Siehl J, Foerster MH, Thiel E. A Clinical Phase I Trial of Gemcitabine and Treosulfan (GeT) in Uveal Melanoma and other Solid Tumors. *Eur J Cancer*, 2004, 40:2047 – 2052.
20. Corrie PG, Shaw J, Spanswick VJ, et al. Phase I trial combining gemcitabine and treosulfan in advanced cutaneous and uveal melanoma patients. *Br J Cancer* 2005; 92:1997-2003.
21. Pföhler C, Cree IA, Ugurel S, et al. Treosulfan and gemcitabine in metastatic uveal melanoma patients: results of a multicenter feasibility study. *Anticancer Drugs* 2003, 14:337-340.
22. Becker JC, Terheyden P, Kampgen E, et al. Treatment of disseminated ocular melanoma with sequential fotemustine, interferon alpha, and interleukin 2. *Br J Cancer*, 2002, 87:840-845.
23. Prescher G, Bornfeld N, Hirche H, Horsthemke B, Jockel KH, Becher R. Prognostic implications of monosomy 3 in uveal melanoma. *Lancet* 1996, 347:1222-1225.
24. Coupland SE, Anastassiou G, Stang A, et al. The prognostic value of cyclin D1, p53, and MDM2 protein expression in uveal melanoma. *J Pathol* 2000, 191:120-126.
25. Hurks HM, Metzelaar-Blok JA, Barthen ER, et al. Expression of epidermal growth factor receptor: risk factor in uveal melanoma. *Invest Ophthalmol Vis Sci* 2000, 41 :2023-2027.
26. Marchand M, van Baren N, Weynants P, Brichard V, Dreno B, Tessier MH, Rankin E, Parmiani G, Arienti F, Humblet Y, Bourlond A, Vanwijck R, Lienard D, Beauduin M, Dietrich PY, Russo V, Kerger J, Masucci G, Jager E, De Greve J, Atzpodien J, Brasseur F, Coulie PG, van der Bruggen P, Boon T. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. *Int J Cancer* 1999, 80:219-30.
27. Scheibenbogen C, Schmittel A, Keilholz U, Allgäuer T, Hofmann U, Max R, Thiel E, Schadendorf D. Phase II trial of vaccination with tyrosinase peptides and GM-CSF in patients with metastatic melanoma. *J Immunotherapy*, 2000, 23:275-281.
28. Mavligit GM, Charnsangavej C, Carrasco CH, Patt YZ, Benjamin RS, Wallace S Regression of ocular melanoma metastatic to the liver after hepatic arterial chemoembolization with cisplatin and polyvinyl sponge. *JAMA*, 1988, 260: 974-976.
29. Feun LG, Reddy KR, Yrizarry JM, Savaraj N, Guerra JJ Jr, Purser RK, Waldman S, Levi JU, Moffatt F, Morrell L A phase I study of chemoembolization with cisplatin and lipiodol for primary and metastatic liver cancer. *Am J Clin Oncol*, 1994, 17:405-410.
30. Feun LG, Reddy KR, Scagnelli T, Yrizarry JM, Guerra JJ, Russell E, Schwartz M, Savaraj N, Livingstone AS, Levi JU, Jeffers LJ, Ardalán B, Schiff ER. A phase I study of chemoembolization with cisplatin, thiotepa, and lipiodol for primary and metastatic liver cancer. *Am J Clin Oncol* 1999, 22:375-380.
31. Kondi ES, Gallitano AL, Evjy JT, Barnard DR Prolonged survival in a patient with hepatic malignant melanoma treated by intra-arterial bleomycin and oral hydroxyurea. *Am J Surg*, 1974, 128: 85-87.
32. Cantore M, Fiorentini G, Aitini E, Davitti B, Cavazzini G, Rabbi C, Lusenti A, Bertani M, Morandi C, Benedini V. Intra-arterial hepatic carboplatin-based chemotherapy for ocular melanoma metastatic to the liver. Report of a phase II study. *Tumori*, 1994, 80:37-39.

33. Leyvraz S, Spataro V, Bauer J, Pampallona S, Salmon R, Dorval T, Meuli R, Gillet M, Lejeune F, Zografos L. Treatment of ocular melanoma metastatic to the liver by hepatic arterial chemotherapy. *J Clin Oncol*, 1997, 15: 2589-2595.
34. Egerer G, Lehnert T, Max R, Naehrer H, Keilholz U, Ho AD. Pilot study of hepatic intraarterial fotemustine chemotherapy for liver metastases from uveal melanoma: a single-center experience with seven patients. *Int J Clin Oncol*, 2001, 6:25-28.
35. Leyvraz S, Bosshard W, Salmon R, Fiorentini G, Keilholz U, Gillet M, Zografos L, Popescu R. Prolonged survival of patients with liver metastases from ocular melanoma: multicentric experience with fotemustine hepatic arterial infusion. *Proc ASCO*, 2002, 21: 1360.